Smith Ernest S. 4

4 · VACCINEX, INC. · Filed Apr 3, 2023

Form 4

Period: 2023-03-31

SVP, Research & CSO

Transactions

Award
Stock Option (Right to Buy)
2023-03-31+40,000→ 40,000 total
Exercise: $0.40Exp: 2033-03-30→ Common Stock (40,000 underlying)

Holdings

Stock Option (Right to Buy)
Exercise: $7.10Exp: 2025-12-22→ Common Stock (40,729 underlying)
40,729
Stock Option (Right to Buy)
Exercise: $2.93Exp: 2031-04-02→ Common Stock (10,000 underlying)
10,000
Stock Option (Right to Buy)
Exercise: $6.07Exp: 2030-02-24→ Common Stock (8,000 underlying)
8,000
Stock Option (Right to Buy)
Exercise: $3.90Exp: 2029-03-14→ Common Stock (8,000 underlying)
8,000
Stock Option (Right to Buy)
Exercise: $1.29Exp: 2032-04-01→ Common Stock (20,000 underlying)
20,000
Common Stock
8,000
Stock Option (Right to Buy)
Exercise: $7.10Exp: 2025-12-23→ Common Stock (5,110 underlying)
5,110

Footnotes (5)

[F1]Exercisable in full as of the date of this report.
[F2]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the February 25, 2020 grant date.
[F3]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date.
[F4]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date.
[F5]This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date.

Documents

1 file